市場調査レポート

商品コード

1687494

出血性疾患治療市場規模、シェア、成長分析：薬の種類別、疾患タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Bleeding Disorders Treatment Market Size, Share, and Growth Analysis, By Drug Type, By Disease Type, By Route of Administration, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年03月18日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 778,146円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 910,284円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,042,422円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
目次

概要

サンプル依頼リストに入れる

出血性疾患治療市場規模は2023年に162億6,000万米ドルとなり、2024年の176億6,000万米ドルから2032年には341億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.6%で成長する見通しです。

出血性疾患治療の世界市場は、いくつかの重要な要因によって大きな成長を遂げています。血友病AやB、フォン・ヴィレブランド病などの有病率の増加により、高度な治療介入の必要性が高まっています。遺伝子組換え凝固因子や遺伝子治療の開発を含む技術の進歩が、市場の拡大をさらに後押ししています。このような進歩にもかかわらず、最先端の治療に伴う高額な費用や特定の地域でのアクセス制限などの課題も残っています。北米と欧州が現在市場を独占しているのは、確立されたヘルスケアインフラと強力な研究イニシアチブのためです。アジア太平洋地域の新興国も、認知度の向上とヘルスケア投資によって成長を遂げています。最近の動向は、この分野のダイナミックな性質を浮き彫りにしています。2023年2月、米国FDAは血友病Aに対するファーストインクラスの高持続性第VIII因子補充療法であるALTUVIIIOを承認しました。さらにバイオマリン社は、重度血友病Aに対する遺伝子治療薬ROCTAVIANの第3相試験で良好な結果が得られたと報告しました。これらの進歩は、予防的治療や革新的な治療への傾向を強調するものであり、出血性疾患管理の将来の展望を形作るものです。しかし、これらの医療技術革新の恩恵を十分に享受するためには、コストの障壁に対処し、公平なアクセスを確保することが依然として重要です。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

AbbVie Inc.（USA）
Bayer AG（Germany）
Novo Nordisk A/S（Denmark）
Pfizer Inc.（USA）
Biogen（USA）
CSL Behring（Australia）
Grifols S.A.（Spain）
Octapharma AG（Switzerland）
BDI Pharma Inc.（USA）
Sanofi（France）
Takeda Pharmaceutical Company Limited（Japan）
F. Hoffmann-La Roche AG（Switzerland）
Amgen Inc.（USA）
Baxter International Inc.（USA）
BioMarin Pharmaceutical Inc.（USA）
Genentech, Inc.（USA）
Kedrion Biopharma Inc.（Italy）
LFB S.A.（France）
Kamada Ltd.（Israel）

結論と提言

Product Code: SQMIG35J2106

Bleeding Disorders Treatment Market size was valued at USD 16.26 Billion in 2023 and is poised to grow from USD 17.66 Billion in 2024 to USD 34.17 Billion by 2032, growing at a CAGR of 8.6% during the forecast period (2025-2032).

The global market for bleeding disorders treatment is experiencing significant growth, driven by several key factors. The increasing prevalence of conditions such as hemophilia A and B, along with von Willebrand disease, has heightened the need for advanced therapeutic interventions. Technological advancements, including the development of recombinant clotting factors and gene therapies, are further propelling market expansion. Despite these advancements, challenges persist, notably the high costs associated with cutting-edge treatments and limited access in certain regions. North America and Europe currently dominate the market, attributed to their established healthcare infrastructures and robust research initiatives. Emerging economies in the Asia-Pacific region are also witnessing growth, driven by increasing awareness and healthcare investments. Recent developments highlight the dynamic nature of this field. In February 2023, the U.S. FDA approved ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement therapy for hemophilia A, offering normal to near-normal factor activity levels with once-weekly dosing. Additionally, BioMarin Pharmaceutical reported positive results from a Phase 3 study of ROCTAVIAN, an investigational gene therapy for severe hemophilia A, indicating sustained efficacy over three years. These advancements underscore a trend towards prophylactic treatments and innovative therapies, shaping the future landscape of bleeding disorder management. However, addressing cost barriers and ensuring equitable access remain critical to fully realizing the benefits of these medical innovations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Bleeding Disorders Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Bleeding Disorders Treatment Market Segments Analysis

Global Bleeding Disorders Treatment Market is segmented by Drug Type, Disease Type, Route of Administration, End User, Distribution Channel and region. Based on Drug Type, the market is segmented into Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants and Others. Based on Disease Type, the market is segmented into Hemophilia A, Hemophilia B, Von Willebrand Disease, Liver Disease and Others. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on End User, the market is segmented into Hospitals, Clinics, Academic Institutions and Homecare Settings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Bleeding Disorders Treatment Market

The rising prevalence of bleeding disorders, such as hemophilia and von Willebrand disease (VWD), has led to an increased demand for advanced treatment options. VWD, for instance, affects up to 1% of the population, often going undiagnosed due to its variable symptoms. Technological advancements in hemostasis management, including the development of recombinant clotting factors and gene therapies, have resulted in more effective and targeted interventions. Innovations like the HemoSonic diagnostic device, which utilizes ultrasound technology to rapidly assess hemostasis, have received FDA approval for use in critical medical scenarios, enhancing patient outcomes.

Restraints in the Bleeding Disorders Treatment Market

The high costs associated with advanced treatments for bleeding disorders, such as hemophilia, present significant barriers to patient access, particularly in economically disadvantaged regions. For instance, gene therapies, while potentially curative, can cost up to $3.5 million per dose, placing a substantial financial strain on healthcare systems and patients. Additionally, regulatory complexities and lengthy approval processes hinder the swift introduction of innovative therapies. Challenges such as costly and restrictive clinical trials and outdated regulatory approval processes impede the advancement of new medical devices from research to clinical use.

Market Trends of the Bleeding Disorders Treatment Market

The increasing focus on personalized medicine aims to tailor treatments to individual patient profiles, optimizing efficacy and minimizing adverse effects. Advancements in gene therapy are emerging as transformative, with ongoing research and clinical trials showcasing the potential for curative approaches to certain bleeding disorders. Additionally, prophylactic treatments are gaining prominence, emphasizing the preventive management of bleeding episodes rather than reactive interventions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape

Global Bleeding Disorders Treatment Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Plasma-Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytics
Fibrin Sealants
Others

Global Bleeding Disorders Treatment Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Hemophilia A
Hemophilia B
Von Willebrand Disease
Liver Disease
Others

Global Bleeding Disorders Treatment Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Intravenous
Subcutaneous
Oral

Global Bleeding Disorders Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Academic Institutions
Homecare Settings

Global Bleeding Disorders Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Compounding Pharmacies

Global Bleeding Disorders Treatment Market Size & CAGR (2025-2032)

North America (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
- US
- Canada
Europe (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Type, Disease Type, Route of Administration, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BDI Pharma Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma Inc. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

出血性疾患治療市場規模、シェア、成長分析：薬の種類別、疾患タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Bleeding Disorders Treatment Market Size, Share, and Growth Analysis, By Drug Type, By Disease Type, By Route of Administration, By End User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

出血性疾患治療市場規模：薬の種類別& CAGR（2025-2032）

出血性疾患治療市場規模：疾患タイプ別& CAGR（2025-2032）

出血性疾患治療市場規模：投与経路別& CAGR（2025-2032）

出血性疾患治療市場規模：エンドユーザー別& CAGR（2025-2032）

出血性疾患治療市場規模：流通チャネル別& CAGR（2025-2032）

出血性疾患治療市場規模：地域別& CAGR（2025-2032）